Intellect

A strategic acquirer (global health insurer, enterprise benefits platform, or large APAC conglomerate) purchases Intellect at $180–250M driven by successful US expansion via the Accresa partnership and revenue tripling to ~$12M. After clearing $52.8M in liquidation preferences, common equity captures $130–200M, implying ~290–340% upside from the $45.26M Series A valuation — though this outcome is implausible within a strict 2-year window.

Intellect closes a Series B at $80–100M post-money, producing a paper step-up of roughly 75–120% from the Series A valuation, but no liquidity event materializes within 2 years; revenue grows modestly to $7–9M on continued APAC penetration. Secondary market access is virtually nonexistent for APAC-based Series A companies, capping realizable 2-year upside at approximately 20% on paper.

Revenue growth stagnates below $5M as Lyra Health and Spring Health — each with hundreds of millions in funding — accelerate enterprise sales globally and compress Intellect's win rate; the company cannot raise a Series B at a flat or up-round, resulting in a punishing down-round or distressed acqui-hire well below $52.8M. With liquidation preferences exceeding current equity value, common shareholders receive little to nothing, implying an 80–90% effective loss.